Fase 3
Claim This Podcastby Lymphoma Experience
Podcast Overview
<p>Tu podcast de análisis crítico de la evidencia en el manejo de Linfomas y Leucemia Linfocítica Crónica.<br><br>Tres especialistas de tres países distintos se juntan a discutir cómo afectan los nuevos (y no tan nuevos) estudios al manejo de pacientes en Latinoamérica.<br><br>Anfitriones:<br>Laura Korin (Argentina)<br>Guilherme Perini (Brasil)<br>Joaquín Díaz (Chile)</p>
Language
🇪🇸
Publishing Since
8/7/2023
1 verified contact email on file for Fase 3
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
March 10, 2026
#19 ¿Qué nos depara la discusión sobre linfoproliferativos en 2026 (y más allá)?
Cambian los tiempos, y este podcast también (un poco). En este episodio, algo más libre, nos permitimos especular sobre qué traerá 2026 y qué nos gustaría que ocurriera en el futuro del manejo de los linfoproliferativos. Al micrófono: •Laura Korin (Argentina) •Guilherme Perini (Brasil) •Joaquín Díaz (Chile)
November 15, 2025
#18 Mundo Cruel: Biespecificos en linfomas b agresivos recaídos/refractarios en la "vida real"
Después de un pequeño "hiato" logramos sentarnos a conversar (y editar) respecto a la brecha eficacia-efectividad que parecen tener los ensayos clínicos pivótales (habitualmente de 1 rama) con los resultados en la llamada "vida real" (mejor "población de práctica clínica"). Nada que un buen randomizado no pueda mejorar. Al micrófono: Laura Korin (Argentina)Guilherme Perini (Brasil)Joaquín Díaz (Chile)Artículo: Brooks TR, Zabor EC, Bedelu YB, Yang X, Karimi YH, Nedved AN, Wang Y, ...
June 19, 2025
#17 Tres Cervezas y un abstract (desde ICML-18 Lugano): POLARGO y la muerte del R-GemOx
The hosts of "Fase 3" analyze the POLARGO study results from the International Conference on Malignant Lymphoma and discuss the implications for the R-GemOx treatment approach.
19 total episodes available
Deep-dive analytics for Fase 3
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Fase 3?
<p>Tu podcast de análisis crítico de la evidencia en el manejo de Linfomas y Leucemia Linfocítica Crónica.<br><br>Tres especialistas de tres países distintos se juntan a discutir cómo afectan los nuevos (y no tan nuevos) estudios al manejo de pacientes en Latinoamérica.<br><br>Anfitriones:<br>Laura Korin (Argentina)<br>Guilherme Perini (Brasil)<br>Joaquín Díaz (Chile)</p> - How often does this podcast release new episodes?
This podcast updates bi-weekly.
- Where can I listen to this podcast?
This podcast is available on 9 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.